

Mr. Iñigo de la Lastra

Head of Secondary Markets

CNMV

Edison, 4

28006 Madrid

Barcelona (Spain), March 28, 2015

RELEVANT FACT

Dear Sir,

In accordance with Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), formerly NATRACEUTICAL SA, submits hereafter the answer to the unaddressed questions from the webcasted conference of 2014 pro forma results, held last March 23. A recording of the conference can be downloaded from the "Investor/Webcasts" section of the company's website (www.reigjofre.com).

- For how long shall the estimated effective tax rate of 12.5% apply, bearing in mind the current tax legislation and the Company's tax credits? The Company estimates that this tax rate shall apply for a period of approximately seven years.
- Does the expansion capex of 17 M€ cover until 2019, in line with the estimated EBITDA growth of 25 M€? This amount is an estimated capex until 2018. Considering the period 2015-2019 the estimated expansion capex shall be 20 M€.
- Are the estimated sales of the three product launches in 2015 incorporated into the growth estimates for 2019? Yes, the Company estimates a contribution of 18 M€ sales in 2019 from these three new products. However, the potential sales of other ongoing research projects referred to in the presentation are not incorporated to the organic growth forecast published.



- Is there any additional risk in Spain by regulatory reforms on antibiotics? The Company does not know whether any new regulatory changes might occur and affect the antibiotic business.

Yours faithfully,

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre SA